SCHEMBL1443539

SCHEMBL1443539

O=Cc1ccc(N2CCN(c3ccccc3)CC2)cc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.70
TRIM33 Q9UPN9 1/20 0.70
ALDH1A1 P00352 6/20 0.69
SMN1; SMN2 Q16637 4/20 0.68
KDM4E B2RXH2 1/20 0.68
CYP2A6 P11509 1/20 0.52
MAPT P10636 3/20 0.51
RAB9A P51151 3/20 0.50
GAA P10253 1/20 0.50
METAP1 P53582 1/20 0.50
TSHR P16473 3/20 0.49
NPC1 O15118 2/20 0.47
POLB P06746 1/20 0.47
USP2 O75604 2/20 0.47
ALOX15 P16050 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077544 0.91 TRIM24 (0.83) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL2561698 0.91 TRIM24 (0.83) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL10070689 0.87 LMNA (0.69) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL5692418 0.86 TRIM24 (0.68) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL4392263 0.83 DRD4 (0.70) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL253732 0.83 TRIM24 (1.00) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL7180854 0.83 TRIM24 (0.91) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL13778829 0.83 MAPT (0.56) ALDH1A1SMN1; SMN2MAPTRAB9AGAA
SCHEMBL7258870 0.82 LMNA (0.64) ALDH1A1SMN1; SMN2MAPTRAB9AGAA
SCHEMBL20639904 0.82 TRIM24 (0.68) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9650362-B2 Inhibitors PROBIODRUG AG (DE) 2017-05-16 US disclosed
US-20160039795-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2016-02-11 US disclosed
EP-2686313-B1 BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-02-03 EP disclosed
US-9173885-B2 Inhibitors PROBIODRUG AG (DE) 2015-11-03 US disclosed
EP-2475428-B1 HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2015-07-01 EP disclosed
CN-102695546-B Heterocylcic derivatives as inhibitors of glutaminyl cyclase PROBIODRUG AG 2014-09-10 CN disclosed
US-20140065095-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2014-03-06 US disclosed
EP-2686313-A1 BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2014-01-22 EP disclosed
US-8530670-B2 Inhibitors PROBIODRUG AG (DE) 2013-09-10 US disclosed
US-8486940-B2 Inhibitors PROBIODRUG AG (DE) 2013-07-16 US disclosed
CN-102695546-A Heterocylcic derivatives as inhibitors of glutaminyl cyclase PROBIODRUG AG 2012-09-26 CN disclosed
US-20120237475-A1 Novel Inhibitors PROBIODRUG AG (DE) 2012-09-20 US disclosed
WO-2012123563-A1 BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-09-20 WO disclosed
EP-2475428-A1 HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2012-07-18 EP disclosed
US-20110092501-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-04-21 US disclosed
WO-2011029920-A1 HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2011-03-17 WO disclosed
US-5942532-A INHIBITORS OF HISTIDINE PROTEIN KINASE; BACTERIA RESISTANT TO OTHER ANTIBIOTICS ORTHO PHARMACEUTICAL CORPORATION (US) 1999-08-24 US disclosed
WO-1999011627-A1 2-SUBSTITUTED PHENYL-BENZIMIDAZOLE ANTIBACTERIAL AGENTS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092501-A1 NOVEL INHIBITORS GLUL, QPCT, GLS TRIM24 1671/4885TRIM33 2822/4885ALDH1A1 2195/4885
US-20160039795-A1 NOVEL INHIBITORS GLUL, QPCT, GLS TRIM24 1671/4885TRIM33 2822/4885ALDH1A1 2195/4885
US-20140065095-A1 NOVEL INHIBITORS GLUL, QPCT, GLS TRIM24 1671/4885TRIM33 2822/4885ALDH1A1 2195/4885
US-20120237475-A1 Novel Inhibitors GLS, NQO2, GLS2 TRIM24 2890/4885TRIM33 3632/4885ALDH1A1 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.